Trial Profile
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Sarilumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 18 Aug 2023 Status changed from not yet recruiting to recruiting.
- 02 Aug 2023 Planned initiation date changed from 31 Jul 2023 to 31 Jul 2024.
- 01 Feb 2023 New trial record